Page 15 - Daptorum Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published: Apr 22, 2021 By Brandon May Clinical-stage biopharmaceutical company, Aptorum Group Limited, announced today that it has entered into a material transfer and option agreement with Yale Universityto study preclinical stage novel immunomodulators targeting autoimmune and oncology diseases. Aptorum Group’s stock is  reportedly up 6% premarket following the announcement of the material transfer and option agreement with Yale. Specifically, the novel immunomodulators under investigation will be used to target rheumatoid arthritis, lupus and sclerosis, among other possible d...

Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced financial results for the fiscal year ended December 31, 2020, and provided an update on clinical and corporate developments. Mr. Darren Lui, President and Executive Director of Aptorum Group Limited, commented "Aptorum's operational plans remain on track. In particular, one of our lead programs, ALS-4 (t...

(1) Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA. Dr. Clark Cheng, Ch...

Aptorum Group Limited (NASDAQ: APM) receives clearance from the Public Health Agency of Canada in regards to its Clinical Trial Application to begin Phase 1 study of ALS-4, its orally taken small molecule drug that is intended to treat infections that are caused by Staphylococcus aureus that includes MRSA. Dr. Clark Cheng, Chief Medical Officer... Aptorum Group Limited (NASDAQ: APM) receives clearance from the Public Health Agency of Canada in regards to its Clinical Trial Application to begin Phase 1 study of ALS-4, its orally taken small molecule drug that is intended to treat infections tha...

Aptorum Group announces submission of Clinical Trial Application 22nd December 2020     Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of ALS-4, an orally administered ...